

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Human Health Holdings Limited

盈健醫療集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1419)

**UPDATE ANNOUNCEMENT ON DISCLOSEABLE TRANSACTION
IN RELATION TO
EXTENSION OF TERM OF THE LIMITED PARTNERSHIP**

Reference is made to the announcements of Human Health Holdings Limited (the “**Company**”) dated 29 May 2019, 9 July 2019, 10 January 2020, 10 July 2024, 23 December 2024 and 25 June 2025 in relation to the Subscription of Partnership Interests in the Limited Partnership (the “**Announcements**”). Unless otherwise defined in this announcement, capitalized terms and expressions used herein shall have the same meanings as those defined in the Announcements.

This announcement is made pursuant to the disclosure obligations of the Company under Rule 14.36 of the Listing Rules.

EXTENSION OF TERM

As disclosed in the Announcements, the Term of the Limited Partnership had been extended to 30 June 2026 .

The Board wishes to announce that on 18 June 2026, the General Partner and the Limited Partners entered into a consent of extension of Term of the Limited Partnership Agreement (the “**Extension Consent**”) pursuant to which, the General Partner and the Limited Partners unanimously agreed to a further extension of the Term until and including 30 June 2027 (the “**Extension**”). Further, the General Partner and the Limited Partners agreed that no Management Fee shall be payable by the Limited Partners to the General Partner for the duration of the Extension or any further extension of the Term thereafter.

All other principal terms of the Limited Partnership Agreement as disclosed in the Announcements remain unchanged.

The terms of the Extension Consent were arrived at after arm’s length negotiations between the General Partner and the Limited Partners. The Board has assessed the exit options available in the Limited Partnership Agreement and has determined that due to the continuing challenging market conditions in the financial sector in the PRC, an exit of its investment in the Limited Partnership pursuant to the Limited Partnership Agreement at this stage would not be beneficial to the Company. The Extension allows the General Partner and the Limited Partners further time to explore more exit options, including but not limited to a disposal of the Partnership Interests to a third party, and as no Management Fee shall be payable by the Company during the Extension, the Company could benefit from better exit terms on its investment without incurring additional costs. The Company will continue to work with the General Partner to identify suitable exit options during the Extension. As such, the Board considers that terms of the Extension Consent and the Extension are fair and reasonable, and are in the interests of the Company and the Shareholders as a whole.

The Company will make further announcement(s) on any further material developments in connection with the Limited Partnership and the investment in New Journey Health Group Limited (previously known as New Journey Hospital Group Limited) as and when appropriate.

By Order of the Board
Human Health Holdings Limited
Chan Kin Ping
Chairman

Hong Kong, 18 June 2026

As at the date of this announcement, the Board comprises Mr. Chan Kin Ping, BBS, JP (also as Chief Executive Officer), Dr. Pang Lai Sheung and Mr. Poon Chun Pong as executive Directors, and Dr. Lui Sun Wing, Mr. Chan Yue Kwong Michael and Mr. Chan Hey Man as independent non-executive Directors.